Join Dogful Login
  • Benny Miles posted an update 1 year, 7 months ago

    The range of HbA1c values also shifted more over time HSP90 (towards lower HbA1c levels) for the RT group than RC group (Figure S1). change in HbA1c from week 0 to week 52 was significantly greater for the RT group (�C0.50% [0.09]) than the RC group (+?0.01 [0.09]; estimated treatment difference [ETD], �C0.51%; 95% CI [�C0.70; �C0.31]; P?<?0.0001), and were similar in magnitude to those for weeks 0�C26 ( DeVries et al., 2012). At week 52, significantly more RT than RC patients achieved an HbA1c <?7.0% (52% vs. 22%, respectively; P?<?0.0001) or HbA1c ��?6.5% (22% vs. 7%, respectively; P?<?0.0001) (see also Table S1). Proportions of patients achieving HbA1c targets were slightly higher at week 52 than week 26 ( Figure S1). FPG decreases up to 26?weeks (DeVries et al., 2012) were sustained in both randomized groups during the extension (Fig.?3B); the mean?��?S.E. reduction from week 0 to week 52 for the RT group was significantly greater than that for the RC group (�C1.91 [0.21] vs. �C0.14 [0.21] mmol/l, respectively; ETD: �C1.77?mmol/l; 95% CI [�C2.24; �C1.30]; P?<?0.0001). Mean self-measured PG levels decreased between week 0 and week 52 in both randomized groups ( Fig.?3C). The mean reductions in postprandial values were significantly greater in the RT group than the RC group for breakfast (ETD �C1.74?mmol/l; 95% CI [�C2.32; �C1.16]; P?<?0.0001) and lunch (ETD �C0.63 [�C1.21; �C0.04]; P?=?0.04). The 3.5-kg weight loss during run-in with metformin?+?liraglutide 1.8?mg was basically maintained over the subsequent 52?weeks in the RT group (Fig.?3d). Weight loss continued in the RC group over the same period, and the mean?��?S.E. weight change for weeks 0�C52 was selleck inhibitor significantly greater for the RC group than RT group (�C1.02 [0.41] vs. �C0.05 [0.42] kg, respectively; ETD: 0.97?kg; 95% CI [0.04; 1.91]; P?=?0.04). The proportion of patients achieving the composite endpoint (HbA1c?<?7.0% without weight gain and major or minor hypoglycemia) at week 52 was greater for the RT group (26%) than RC group (17%) but the treatment difference was not significant (P?=?0.06; Table S1). These proportions were nevertheless numerically increased over those at 26?weeks ( DeVries et al., 2012). Mean prescribed insulin doses increased from 10 U at week 0 to 39.5 U (0.41?U/kg) at week 26, and were then stable to study end (42 U [0.45?U/kg] at week 50) (Fig.?3e). Mean self-measured FPG decreased from 7.9?mmol/l at week 1 to 6.1?mmol/l at week Etoposide purchase 50. The titration algorithm was apparently followed, with mean prescribed insulin doses matching closely to recommended doses (Figure S2). Lipid profile improvements during the 26-week main period (DeVries et al., 2012) were generally sustained or enhanced during weeks 27�C52 (data not shown). Changes in lipid profiles for weeks 0�C52 were not significantly different between randomized groups, except for a greater increase in high-density lipoprotein cholesterol levels for the RT group than RC group (0.07 [0.02] vs.